Valsartan ameliorates high glucose-induced peritoneal fibrosis by blocking mTORC1 signaling
Jing Liu(Nanjing Medical University), Chunming Jiang(Nanjing Drum Tower Hospital), Qiuyuan Shao(Nanjing Drum Tower Hospital), Qingyan Zhang(University of South China), Miao Zhang(Harbin Institute of Technology), Wei Zhu(Ministry of Education of the People's Republic of China), Bo Jin(Fudan University), Pengfei Xu(Nanjing Drum Tower Hospital), Yuan Feng, Cheng Sun(Nanjing Drum Tower Hospital), Yangyang Xia(National Clinical Research)
Cited by 16
Related Papers
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
|Annals of the Rheumatic Diseases|2011|412
Interferon and Biologic Signatures in Dermatomyositis Skin: Specificity and Heterogeneity across Diseases
|PLoS ONE|2012|196
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
|Annals of the Rheumatic Diseases|2013|168